Here's your chance to ask the lead physicist from Brigham and Women's Hospital anything you want to know about how to successfully launch a MRIdian program, from commissioning to adaptation on first treatment. They've treated more than 100 patients on MRIdian in the first nine months, so here's your chance to learn tips and tricks from the experts in operational excellence.
Christopher Williams, PhD
Chief, MR-Based Adaptive Treatment
Dr. Williams is an Instructor of Radiation Oncology at Harvard Medical School and a staff physicist at the Brigham & Women’s Hospital and Dana-Farber Cancer Institute. He is the physics lead of the MR-guided adaptive radiation therapy program and a member of the MRIdian adaptive treatment team. He received his BS in physics from Stanford University, his Ph.D. in physics from MIT, and is a graduate of the Harvard Medical Physics Residency Program.
Vice President of Clinical Marketing
Michael Saracen is Vice President of Clinical Marketing at ViewRay Inc., where he has worked since 2012 helping with the development, productization, and launch of the MRIdian and MRIdian Linac products into the commercial market globally. He has nearly 25 year’s experience with innovating, patenting, developing, and launching new products into the medical device industry. With over 18 years specifically focused on Radiation Oncology working for companies such as Radionics, CIVCO, and Accuray. Michael received his Masters from Brown University in Biomaterials and Artificial Organs and has 19 issued patents covering robotics, QA, tracking & vision systems, and treatment planning software.